Search Results - "Dechow, Tobias Nicolaas"

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial by Masetti, Michael, Al-Batran, Salah-Eddin, Goetze, Thorsten Oliver, Thuss-Patience, Peter C., Riera-Knorrenschild, Jorge, Goekkurt, Eray, Folprecht, Gunnar, Ettrich, Thomas Jens, Lindig, Udo, Luley, Kim Barbara, Pink, Daniel, Dechow, Tobias Nicolaas, Sookthai, Disorn, Junge, Sabine, Pauligk, Claudia, Lorenzen, Sylvie

“…4043 Background: FOLFOX plus nivolumab has become standard of care for first-line therapy of patients (pts) with advanced gastroesophageal cancer (aGEC). The…”
Get full text

Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) by Lorenzen, Sylvie, Goetze, Thorsten Oliver, Thuss-Patience, Peter C., Riera-Knorrenschild, Jorge, Goekkurt, Eray, Dechow, Tobias Nicolaas, Ettrich, Thomas Jens, Hofheinz, Ralf Dieter, Luley, Kim Barbara, Pink, Daniel, Lindig, Udo, Folprecht, Gunnar, Schuch, Gunter, Bitzer, Michael, Heinemann, Volker, Angermeier, Stefan, Bolling, Claus, Junge, Sabine, Pauligk, Claudia, Al-Batran, Salah-Eddin

“…4050 Background: FOLFOX plus nivolumab has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas (EGA). The…”
Get full text

FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO by Lorenzen, Sylvie, Goetze, Thorsten Oliver, Hofheinz, Ralf Dieter, Thuss-Patience, Peter C., Dechow, Tobias Nicolaas, Riera-Knorrenschild, Jorge, Schuch, Gunter, Luley, Kim Barbara, Koch, Christine, Goekkurt, Eray, Schmalenberg, Harald, Ettrich, Thomas Jens, Lindig, Udo, Pink, Daniel, Bitzer, Michael, Bolling, Claus, Homann, Nils, Junge, Sabine, Pauligk, Claudia, Al-Batran, Salah-Eddin

“…4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FLOT…”
Get full text

Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study by Dechow, Tobias Nicolaas, Riera-Knorrenschild, Jorge, Hackanson, Björn, Fischer von Weikersthal, Ludwig, Schulz, Holger, Chiabudini, Marco, Timm, Barbara, Zerbes, Ralf, Potthoff, Karin

“…Abstract only e21611 Background: Collecting real-world evidence is required not only to evaluate effectiveness and safety in routine clinical practice, but to…”
Get full text

FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO by Lorenzen, Sylvie, Thuss-Patience, Peter C., Riera Knorrenschild, Jorge, Goekkurt, Eray, Dechow, Tobias Nicolaas, Hofheinz, Ralf-Dieter, Luley, Kim Barbara, Ettrich, Thomas Jens, Pink, Daniel, Lindig, Udo, Folprecht, Gunnar, Schuch, Gunter, Bitzer, Michael, Bolling, Claus, Homann, Nils, Junge, Sabine, Pauligk, Claudia, Gaiser, Timo, Goetze, Thorsten Oliver, Al-Batran, Salah-Eddin

“…4043 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. The…”
Get full text

RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316) by Kasper, Stefan, Goetze, Thorsten Oliver, Stintzing, Sebastian, Hofheinz, Ralf Dieter, Sinn, Marianne, Dechow, Tobias Nicolaas, Ettrich, Thomas Jens, Keitel, Verena, Graeven, Ullrich, Fischer von Weikersthal, Ludwig, Kolov, Alexander, Edelmann, Thomas, Stein, Alexander, Trarbach, Tanja, Junge, Sabine, Pauligk, Claudia, Virchow, Isabel, Siveke, Jens T, Al-Batran, Salah-Eddin, Schuler, Martin H.

“…Abstract only 3566 Background: Patients (pts) with mCRC progressing on standard chemotherapy have limited therapeutic options. Trifluridine/tipiracil (TAS102)…”
Get full text

Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial by Haas, Michael, Abdul-Ahad, Ayad, Snijder, Robert, Waldschmidt, Dirk Thomas, Stahl, Michael, Reinacher-Schick, Anke C., Freiberg-Richter, Jens, Kaiser, Florian, Kanzler, Stephan, Frickhofen, Norbert, Seufferlein, Thomas, Dechow, Tobias Nicolaas, Mahlberg, Rolf, Malfertheiner, Peter, Illerhaus, Gerald, Kubicka, Stefan, Held, Swantje, Boeck, Stefan Hubert, von Bergwelt-Baildon, Michael, Heinemann, Volker

“…Abstract only e16786 Background: The phase II ACCEPT trial included 119 patients (pts) with histologically proven pancreatic cancer without any previous…”
Get full text

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316) by Kasper, Stefan, zur Hausen, Gerrit, Stein, Alexander, Stintzing, Sebastian, Berger, Andreas, Loges, Sonja, Hofheinz, Ralf, Trarbach, Tanja, Graeven, Ullrich, Fischer von Weikersthal, Ludwig, Goetze, Thorsten Oliver, Hagen, Volker A., Burock, Susen, Hoffmeister, Albrecht, Dechow, Tobias Nicolaas, Pauligk, Claudia, Virchow, Isabel, Siveke, Jens T, Al-Batran, Salah-Eddin, Schuler, Martin H.

“…Abstract only TPS3617 Background: Patients with metastatic colorectal cancer (mCRC) with progressive disease on/after or who are intolerant to…”
Get full text

A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC) by Lorenzen, Sylvie, Riera Knorrenschild, Jorge, Pauligk, Claudia, Goetze, Thorsten Oliver, Hegewisch-Becker, Susanna, Seraphin, Jörg, Thuss-Patience, Peter C., Kopp, Hans-Georg, Dechow, Tobias Nicolaas, Vogel, Arndt, Luley, Kim Barbara, Pink, Daniel, Stahl, Michael, Kullmann, Frank, Hebart, Holger Frithjof, Siveke, Jens T., Egger, Matthias, Homann, Nils, Probst, Stephan, Al-Batran, Salah-Eddin

“…Abstract only 4027 Background: There is a need for effective treatments in the second- or further line setting in advanced gastric cancer, especially for new…”
Get full text

A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC) by Al-Batran, Salah-Eddin, Riera-Knorrenschild, Jorge, Pauligk, Claudia, Goetze, Thorsten Oliver, Hegewisch-Becker, Susanna, Seraphin, Jörg, Thuss-Patience, Peter C., Kopp, Hans-Georg, Dechow, Tobias Nicolaas, Vogel, Arndt, Luley, Kim Barbara, Pink, Daniel, Stahl, Michael, Kullmann, Frank, Hebart, Holger Frithjof, Siveke, Jens T., Egger, Matthias, Homann, Nils, Probst, Stephan, Lorenzen, Sylvie

“…Abstract only 4 Background: There is a need for effective treatments in the second- or further line setting in advanced gastric cancer, especially for new…”
Get full text